Eggers A E
Cancer Res. 1976 Jun;36(6):2085-9.
A C57BL/6 (B6) methylcholanthrene-induced solid tumor grows progressively in BALB/c mice. The BALB/c mice fail to develop in their spleens cytotoxic lymphocytes directed against the histocompatibility (H-) antigens of the tumor. A B6 skin graft is rejected normally by mice with the progressively growing B6 tumor and skin graft rejection has no influence on the growth of the tumor. Tissue culture-carried tumor cells work satisfactorily as target cells in a 51Cr release assay with effector lymphocytes immunized against B6 H-antigens, but the tumor cells will not work as an immunogen for H-antigens for an in vitro immunization. "Fresh" tumor cells removed from their in vivo environment and separated on a discontinuous bovine serum albumin gradient also work as target cells. The conclusion is drawn that the host cytotoxic lymphocyte response against the tumor, as defined by a short-term 51Cr release assay, suffers from both sensitization and effector stage defects that probably do not involve serum factors or suppressor cells.
C57BL/6（B6）甲基胆蒽诱导的实体瘤在BALB/c小鼠体内逐渐生长。BALB/c小鼠脾脏中未能产生针对肿瘤组织相容性（H-）抗原的细胞毒性淋巴细胞。带有逐渐生长的B6肿瘤的小鼠能正常排斥B6皮肤移植，且皮肤移植排斥对肿瘤生长无影响。在针对B6 H抗原免疫的效应淋巴细胞进行的51Cr释放试验中，组织培养携带的肿瘤细胞作为靶细胞效果良好，但肿瘤细胞不能作为H抗原的免疫原用于体外免疫。从体内环境中取出并在不连续牛血清白蛋白梯度上分离的“新鲜”肿瘤细胞也可作为靶细胞。得出的结论是，根据短期51Cr释放试验所定义的宿主对肿瘤的细胞毒性淋巴细胞反应，在致敏和效应阶段均存在缺陷，这可能与血清因子或抑制细胞无关。
